Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03651128
Title Efficacy and Safety Study of bb2121 Versus Standard Triplet Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) (KarMMa-3)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Celgene

multiple myeloma


Bortezomib + Daratumumab + Dexamethasone

Idecabtagene Vicleucel

Dexamethasone + Ixazomib + Lenalidomide

Daratumumab + Dexamethasone + Pomalidomide

Age Groups: senior | adult
Covered Countries USA | ITA | FRA | ESP | DEU | CAN | BEL

No variant requirements are available.